News & Updates
Filter by Specialty:
On-body injector on par with traditional injection in preventing severe neutropaenia
Pegfilgrastim on-body injectors (OBI) are as effective as traditional injection for the prevention of severe neutropaenia (SN), neutropaenic fever, and neutropaenia in breast cancer patients, reveals a study.
On-body injector on par with traditional injection in preventing severe neutropaenia
05 Feb 2022
Obese breast cancer patients on T-DM1 prone to more treatment adjustments
More treatment modifications secondary to adverse events appear necessary among obese patients receiving ado-trastuzumab emtansine (T-DM1), an antibody-drug conjugate indicated for the treatment of HER2-positive breast cancer, relative to nonobese counterparts, reports a study.
Obese breast cancer patients on T-DM1 prone to more treatment adjustments
04 Feb 2022
Quercetin augments therapeutic benefit of antivirals for COVID-19
In patients hospitalized for severe COVID-19, adding the plant flavonoid quercetin to the antiviral drugs remdesivir or favipiravir reduced hospitalization period and levels of inflammatory markers related to the pathogenesis of SARS-CoV-2, thus preventing the progression of the disease into its critical phase, suggests an open-label study from Iran.
Quercetin augments therapeutic benefit of antivirals for COVID-19
03 Feb 2022
Tirzepatide regulates metabolites, lipids in T2D
Treatment with tirzepatide leads to a reduction in body weight and improvement in glycaemic control in individuals with type 2 diabetes (T2D), reports a study. In addition, it modulates metabolites associated with T2D risk and metabolic dysregulation that is consistent with improved metabolic health.